September 18, 2024 01:00 PM EDTUpdated 01:16 PM

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Zachary Brennan

Senior Editor

New York-based Applied Therapeutics disclosed on Wednesday that the FDA has canceled an October advisory committee meeting for its potential treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Tang Capital’s Concentra bids for Singular Genomics days after Deerfield offer

Breaking down silos with a new quantitative approach to drug development